Status:

ACTIVE_NOT_RECRUITING

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Prostate Adenocarcinoma

Eligibility:

MALE

18+ years

Brief Summary

This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of...

Detailed Description

PRIMARY OBJECTIVES: I. To assess reproducibility of quantitative spectroscopic and imaging parameters in hyperpolarized 13-C pyruvate magnetic resonance spectroscopic imaging (MRSI), including kpl, w...

Eligibility Criteria

Inclusion

  • Biopsy proven prostate adenocarcinoma (Arm 1 \& 2)
  • Clinically appropriate for active surveillance (Arm 1)
  • Prior prostate biopsy must have been performed at least 5 weeks prior imaging (Arm 1 \& 2)
  • Patient must be scheduled to undergo radical prostatectomy within 6 months of multi-parametric magnetic resonance imaging (MP-MRI) + hyperpolarized (HP) \[1-13C\]-pyruvate imaging, consistent with American College of Radiology Imaging Network (ACRIN) Protocol: ACRIN 6659 (Arm 2)
  • At least 10% of enrolled patients will have high risk of disease progression (Cancer of the Prostate Risk Assessment - \[CAPRA\] 6-10) and no more than 50% of enrolled patients will have low risk of progression (CAPRA \< 3) (Arm 2)

Exclusion

  • Contraindication to MRI (Arm 1 \& 2)
  • Allergy to gadavist intravenous contrast (Arm 1 \& 2)
  • Any known medical history of arrhythmias such as atrial fib, etc. (Arm 1 \& 2)
  • Prior therapy for prostate cancer, except for 5-alpha reductase inhibitor discontinued at least one month prior to imaging (Arm 1 \& 2)

Key Trial Info

Start Date :

December 19 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 30 2026

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT04286386

Start Date

December 19 2019

End Date

April 30 2026

Last Update

October 27 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | DecenTrialz